MARTA HESHELMAN: Open Payments
NPI 1730540592 · BLOOMINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,177 in 65 payments from 23 companies in 2025. Trend: 2023 $518 · 2024 $937 · 2025 $1,177
Food & beverage: $1,177
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $184 |
| Verona Pharma, Inc. | 8 | $158 |
| Novartis Pharmaceuticals Corporation | 8 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $87 |
| Azurity Pharmaceuticals, Inc. | 3 | $64 |
| ABBVIE INC. | 3 | $57 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $49 |
| Stryker Corporation | 1 | $46 |
| UCB, Inc. | 2 | $43 |
Products named: Ohtuvayre, LEQVIO, CAPLYTA, Ozempic, HORIZANT, JOURNAVX, ORTHOLOC 2 LAPIFUSE, VRAYLAR.
Industry payments across IN — which companies pay providers there.
